Still open questions of this strategy are the mechanism of action of CFTR correctors in sarcoglycanopathy, the evaluation of possible side effects, and the broadness of efficacy in a single subtype and all four subtypes of sarcoglycanopathy. Here, CFTR is linked to sarcoglycanopathy.